Mankind Pharma on Monday said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to initiate a Phase 1 clinical trial for a molecule under development for the treatment of multiple autoimmune disorders.
The molecule is being developed for the treatment of multiple autoimmune disorders, including rheumatoid arthritis, ulcerative colitis, plaque psoriasis, and alopecia.
Developed at the Mankind Research Centre,
The molecule is being developed for the treatment of multiple autoimmune disorders, including rheumatoid arthritis, ulcerative colitis, plaque psoriasis, and alopecia.
Developed at the Mankind Research Centre,